U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H29N3O3.ClH
Molecular Weight 419.945
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of N-(5-(DIETHYLAMINO)-1-PHENYLPENTYL)-4-NITROBENZAMIDE HYDROCHLORIDE

SMILES

Cl.CCN(CC)CCCCC(NC(=O)C1=CC=C(C=C1)[N+]([O-])=O)C2=CC=CC=C2

InChI

InChIKey=CHCBAYRWJULIDW-UHFFFAOYSA-N
InChI=1S/C22H29N3O3.ClH/c1-3-24(4-2)17-9-8-12-21(18-10-6-5-7-11-18)23-22(26)19-13-15-20(16-14-19)25(27)28;/h5-7,10-11,13-16,21H,3-4,8-9,12,17H2,1-2H3,(H,23,26);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H29N3O3
Molecular Weight 383.484
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nebentan (YM598) is an orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. The inhibitory dissociation constant value of YM598 was 0.772 nM for native human ETA receptors, and 143 nM for native human ETB subtypes. The calculated selectivity ratio of YM598 for ETA versus ETB receptors was 222. In pithed rats, YM598 inhibited the big endothelin-1 (1 nmol/kg)-induced pressor response in a dose-dependent manner, after both intravenous and oral administration. YM598 showed not only superior antagonistic activity and higher-selectivity for endothelin ET(A) receptor in vitro, but at least a 30-fold higher potency in vivo than bosentan.

Approval Year

Targets

Targets

PubMed

PubMed

TitleDatePubMed
In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract.
2008-02-12
Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats.
2004-02
Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist.
2003-09-30
Patents

Sample Use Guides

In the in vivo study, endothelin-1 induced the elevation of non-prostatic urethral pressure as well as prostatic urethral pressure even in the presence of tamsulosin (10 microg/kg, i.v.) in anesthetized male dogs. Nebentan (0.1-3 mg/kg, i.v.) inhibited these endothelin-1-induced contractile responses in a dose-dependent fashion.
Route of Administration: Intravenous
In the in vitro study, endothelin-1 induced contractile responses in isolated rabbit bladder base, urethra, and prostate tissues. Nebentan (10(-7)-10(-5) M) antagonized endothelin-1-induced contractile responses without affecting the maximal responses. YM598 inhibited [125I]endothelin-1 binding to cloned human endothelin ET(A) and ET(B) receptor, with K(i) of 0.697 and 569 nM, and inhibited endothelin-1-induced increases in intracellular Ca(2+) concentration in human and rat endothelin ET(A) receptor. YM598 also inhibited endothelin-1-induced vasoconstriction in isolated rat aorta with a pA(2) value of 7.6.
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:43:05 GMT 2025
Edited
by admin
on Mon Mar 31 23:43:05 GMT 2025
Record UNII
N4S59ZCS33
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NIBENTAN
Preferred Name English
N-(5-(DIETHYLAMINO)-1-PHENYLPENTYL)-4-NITROBENZAMIDE HYDROCHLORIDE
Systematic Name English
1-PHENYL-1-((P-NITROBENZOYL)AMINO)-5-(N,N-DIETHYLAMINO)PENTANE HYDROCHLORIDE
Systematic Name English
BENZAMIDE, N-(5-(DIETHYLAMINO)-1-PHENYLPENTYL)-4-NITRO-, HYDROCHLORIDE (1:1)
Systematic Name English
Nibentan [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
177905
Created by admin on Mon Mar 31 23:43:05 GMT 2025 , Edited by admin on Mon Mar 31 23:43:05 GMT 2025
PRIMARY
FDA UNII
N4S59ZCS33
Created by admin on Mon Mar 31 23:43:05 GMT 2025 , Edited by admin on Mon Mar 31 23:43:05 GMT 2025
PRIMARY
CAS
157832-56-9
Created by admin on Mon Mar 31 23:43:05 GMT 2025 , Edited by admin on Mon Mar 31 23:43:05 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE